SEC Form 13F Summary: Merck & Co., Inc.
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Merck & Co., Inc. for the reporting period ending June 30, 2026. The document discloses the company's holdings of equity securities as of the end of the quarter. It does not contain operational or financial performance data for Merck itself, but rather details its investment portfolio.
Key Financial Metrics and Portfolio Composition
The filing lists 13 equity positions, primarily concentrated in the biotechnology and pharmaceutical sectors. The total value of these specific disclosed holdings is approximately $307.1 million based on the sum of the "Value" column.
| Issuer | Shares Held | Value (USD) | Voting Authority |
|---|---|---|---|
| Personalis Inc | 14,044,943 | $188,202,236 | Sole |
| Moderna Inc | 2,308,190 | $161,642,545 | Sole |
| Aktis Oncology Inc | 952,844 | $30,710,162 | Sole |
| Alector Inc | 3,545,719 | $7,126,896 | Sole |
| Eikon Therapeutics Inc | 1,666,666 | $21,749,991 | Sole |
| Entrada Therapeutics Inc | 1,739,768 | $12,804,692 | Sole |
| Evaxion Biotech A/S | 1,214,126 | $3,763,791 | Sole |
| Kymera Therapeutics Inc | 772,165 | $88,544,161 | Sole |
| Neuphoria Therapeutics Inc | 10,027 | $43,818 | Sole |
| Sutro Biopharma Inc | 272,351 | $9,042,053 | Sole |
| Tuhura Biosciences Inc | 19,445 | $45,501 | Sole |
| Viridian Therapeutics Inc | 93,414 | $1,716,015 | Sole |
| Xilio Therapeutics Inc | 105,982 | $1,015,308 | Sole |
Note: The filing text does not provide clear values for Merck's own revenue, profit, cash flow, debt, or liquidity. This form only reports investment holdings.
Material Changes and Guidance
The filing text does not provide comparative data against the prior period (March 31, 2026) to determine material changes in holdings. Consequently, no analysis of increases or decreases in positions can be derived from this document alone. There is no management commentary, guidance, or discussion of risks and contingencies included in this specific filing type.
Investor Verification Checklist
- Portfolio Concentration: Verify the strategic rationale for the two largest holdings (Personalis Inc and Moderna Inc), which represent the majority of the disclosed value.
- Valuation Accuracy: Confirm the share prices used for the June 30, 2026 valuation against market data for that date.
- Complete Holdings: Determine if this table represents the entirety of Merck's equity portfolio or if other holdings were excluded or reported in separate filings.
- Operational Performance: Consult Merck's Form 10-Q or 10-K for the actual financial performance (revenue, earnings, cash flow) of the company, as this Form 13F does not contain such data.